Clinical Trial Update: Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluated combining MAGE-A3 and NY-ESO-1 immunotherapies with DTPACE chemotherapy and autologous transplantation in multipl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DTPACE chemotherapy regimen
• MAGE-A3 immunotherapy
• NY-ESO-1 immunotherapy

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2013-06-24